The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Tardive Dyskinesia Treatment Medicine Market Research Report 2025
Synopsis
Tardive dyskinesia (TD) is a neurological disorder characterized by involuntary and repetitive movements, often affecting the face, tongue, lips, and other parts of the body. It is most commonly associated with the long-term use of certain medications, particularly antipsychotic medications used to treat conditions like schizophrenia and bipolar disorder. Tardive dyskinesia can be a challenging condition to manage, and treatment options aim to alleviate symptoms and improve the quality of life for affected individuals.
Global Tardive Dyskinesia Treatment Medicine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tardive Dyskinesia Treatment Medicine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tardive Dyskinesia Treatment Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva Pharmaceutical
Neurocrine Biosciences
Sun Pharmaceutical
SteriMax
Adamas Pharmaceuticals (Supernus)
AbbVie
Segment by Type
Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors
Botulinum Toxin
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Tardive Dyskinesia Treatment Medicine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Tardive dyskinesia (TD) is a neurological disorder characterized by involuntary and repetitive movements, often affecting the face, tongue, lips, and other parts of the body. It is most commonly associated with the long-term use of certain medications, particularly antipsychotic medications used to treat conditions like schizophrenia and bipolar disorder. Tardive dyskinesia can be a challenging condition to manage, and treatment options aim to alleviate symptoms and improve the quality of life for affected individuals.
Global Tardive Dyskinesia Treatment Medicine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tardive Dyskinesia Treatment Medicine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tardive Dyskinesia Treatment Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva Pharmaceutical
Neurocrine Biosciences
Sun Pharmaceutical
SteriMax
Adamas Pharmaceuticals (Supernus)
AbbVie
Segment by Type
Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors
Botulinum Toxin
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Tardive Dyskinesia Treatment Medicine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tardive Dyskinesia Treatment Medicine Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Vesicular Monoamine Transporter 2 (Vmat2) Inhibitors
1.2.3 Botulinum Toxin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Tardive Dyskinesia Treatment Medicine Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tardive Dyskinesia Treatment Medicine Market Perspective (2018-2029)
2.2 Tardive Dyskinesia Treatment Medicine Growth Trends by Region
2.2.1 Global Tardive Dyskinesia Treatment Medicine Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tardive Dyskinesia Treatment Medicine Historic Market Size by Region (2018-2023)
2.2.3 Tardive Dyskinesia Treatment Medicine Forecasted Market Size by Region (2024-2029)
2.3 Tardive Dyskinesia Treatment Medicine Market Dynamics
2.3.1 Tardive Dyskinesia Treatment Medicine Industry Trends
2.3.2 Tardive Dyskinesia Treatment Medicine Market Drivers
2.3.3 Tardive Dyskinesia Treatment Medicine Market Challenges
2.3.4 Tardive Dyskinesia Treatment Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tardive Dyskinesia Treatment Medicine Players by Revenue
3.1.1 Global Top Tardive Dyskinesia Treatment Medicine Players by Revenue (2018-2023)
3.1.2 Global Tardive Dyskinesia Treatment Medicine Revenue Market Share by Players (2018-2023)
3.2 Global Tardive Dyskinesia Treatment Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tardive Dyskinesia Treatment Medicine Revenue
3.4 Global Tardive Dyskinesia Treatment Medicine Market Concentration Ratio
3.4.1 Global Tardive Dyskinesia Treatment Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tardive Dyskinesia Treatment Medicine Revenue in 2022
3.5 Tardive Dyskinesia Treatment Medicine Key Players Head office and Area Served
3.6 Key Players Tardive Dyskinesia Treatment Medicine Product Solution and Service
3.7 Date of Enter into Tardive Dyskinesia Treatment Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tardive Dyskinesia Treatment Medicine Breakdown Data by Type
4.1 Global Tardive Dyskinesia Treatment Medicine Historic Market Size by Type (2018-2023)
4.2 Global Tardive Dyskinesia Treatment Medicine Forecasted Market Size by Type (2024-2029)
5 Tardive Dyskinesia Treatment Medicine Breakdown Data by Application
5.1 Global Tardive Dyskinesia Treatment Medicine Historic Market Size by Application (2018-2023)
5.2 Global Tardive Dyskinesia Treatment Medicine Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tardive Dyskinesia Treatment Medicine Market Size (2018-2029)
6.2 North America Tardive Dyskinesia Treatment Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tardive Dyskinesia Treatment Medicine Market Size by Country (2018-2023)
6.4 North America Tardive Dyskinesia Treatment Medicine Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tardive Dyskinesia Treatment Medicine Market Size (2018-2029)
7.2 Europe Tardive Dyskinesia Treatment Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tardive Dyskinesia Treatment Medicine Market Size by Country (2018-2023)
7.4 Europe Tardive Dyskinesia Treatment Medicine Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tardive Dyskinesia Treatment Medicine Market Size (2018-2029)
8.2 Asia-Pacific Tardive Dyskinesia Treatment Medicine Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tardive Dyskinesia Treatment Medicine Market Size by Region (2018-2023)
8.4 Asia-Pacific Tardive Dyskinesia Treatment Medicine Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tardive Dyskinesia Treatment Medicine Market Size (2018-2029)
9.2 Latin America Tardive Dyskinesia Treatment Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tardive Dyskinesia Treatment Medicine Market Size by Country (2018-2023)
9.4 Latin America Tardive Dyskinesia Treatment Medicine Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tardive Dyskinesia Treatment Medicine Market Size (2018-2029)
10.2 Middle East & Africa Tardive Dyskinesia Treatment Medicine Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tardive Dyskinesia Treatment Medicine Market Size by Country (2018-2023)
10.4 Middle East & Africa Tardive Dyskinesia Treatment Medicine Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva Pharmaceutical
11.1.1 Teva Pharmaceutical Company Detail
11.1.2 Teva Pharmaceutical Business Overview
11.1.3 Teva Pharmaceutical Tardive Dyskinesia Treatment Medicine Introduction
11.1.4 Teva Pharmaceutical Revenue in Tardive Dyskinesia Treatment Medicine Business (2018-2023)
11.1.5 Teva Pharmaceutical Recent Development
11.2 Neurocrine Biosciences
11.2.1 Neurocrine Biosciences Company Detail
11.2.2 Neurocrine Biosciences Business Overview
11.2.3 Neurocrine Biosciences Tardive Dyskinesia Treatment Medicine Introduction
11.2.4 Neurocrine Biosciences Revenue in Tardive Dyskinesia Treatment Medicine Business (2018-2023)
11.2.5 Neurocrine Biosciences Recent Development
11.3 Sun Pharmaceutical
11.3.1 Sun Pharmaceutical Company Detail
11.3.2 Sun Pharmaceutical Business Overview
11.3.3 Sun Pharmaceutical Tardive Dyskinesia Treatment Medicine Introduction
11.3.4 Sun Pharmaceutical Revenue in Tardive Dyskinesia Treatment Medicine Business (2018-2023)
11.3.5 Sun Pharmaceutical Recent Development
11.4 SteriMax
11.4.1 SteriMax Company Detail
11.4.2 SteriMax Business Overview
11.4.3 SteriMax Tardive Dyskinesia Treatment Medicine Introduction
11.4.4 SteriMax Revenue in Tardive Dyskinesia Treatment Medicine Business (2018-2023)
11.4.5 SteriMax Recent Development
11.5 Adamas Pharmaceuticals (Supernus)
11.5.1 Adamas Pharmaceuticals (Supernus) Company Detail
11.5.2 Adamas Pharmaceuticals (Supernus) Business Overview
11.5.3 Adamas Pharmaceuticals (Supernus) Tardive Dyskinesia Treatment Medicine Introduction
11.5.4 Adamas Pharmaceuticals (Supernus) Revenue in Tardive Dyskinesia Treatment Medicine Business (2018-2023)
11.5.5 Adamas Pharmaceuticals (Supernus) Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Tardive Dyskinesia Treatment Medicine Introduction
11.6.4 AbbVie Revenue in Tardive Dyskinesia Treatment Medicine Business (2018-2023)
11.6.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
